Clinical Trials
22 trialsNCT02971501 2026-05-29
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04250545 2026-05-26
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02696993 2026-05-20
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05012254 2026-05-05
NIVIPI-Brain
Fundación GECP
Phase 2 Active not recruiting
NCT02589522 2026-04-29
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06282874 2026-04-09
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Active not recruiting
NCT05703269 2026-04-06
HYPOGRYPHE
Wake Forest University Health Sciences
Phase NA Active not recruiting
NCT07491211 2026-03-27
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Fudan University
Active not recruiting
NCT04899908 2026-03-19
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT04516070 2026-03-05
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07389642 2026-02-05
OligoLung
University Hospital, Bordeaux
Active not recruiting
NCT05305365 2025-12-23
Study Assessing QBS72S For Treating Brain Metastases
Stanford University
Phase 2 Active not recruiting
NCT05256290 2025-12-09
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics, Inc.
Phase 1/2 Active not recruiting
NCT06020066 2025-09-15
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Fudan University
Phase 2 Active not recruiting
NCT03753685 2025-07-23
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Fudan University
Phase 2 Active not recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT06557187 2025-04-18
Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC
Jiangsu Cancer Institute & Hospital
Phase NA Active not recruiting
NCT03769103 2024-10-31
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT03075072 2024-10-23
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
Dana-Farber Cancer Institute
Phase NA Active not recruiting
NCT03391362 2024-10-23
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
Dana-Farber Cancer Institute
Phase NA Active not recruiting
NCT03870464 2024-05-07
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
University of Southern Denmark
Active not recruiting